Program will Accelerate Commercialization Efforts by Early Stage Companies and Late Stage Academic Research for Infectious Disease Solutions While Growing the State’s Life Science Economy
Round One Recommended Awardees Here
Governor Kathy Hochul today announced the first round of awardees of the $40 million New York State Biodefense Commercialization Fund. The program was created to accelerate the development and commercialization of life science innovations that address serious infectious disease threats including COVID-19 and its variants, while also creating jobs and encouraging continued growth across New York’s expanding life science industry. Upon board approval by Empire State Development, eighteen grants will be awarded for a total grant commitment of $15,292,418.
“New York State was hit first and hit hardest by COVID-19, and even as New York continues its progress in combating this virus and building back stronger, we’re taking measures to ensure we’re prepared for the future,” Governor Hochul said. “These grants help promote the growth of New York State’s visionary life science companies, while also increasing our preparedness against current and future infectious disease threats, helping create a safer, stronger Empire State for years to come.”
New York State Empire State Development Acting Commissioner and President and CEO-designate Hope Knight said, “Supporting innovative companies focused on COVID-19 and other infectious diseases through the State's Life Science Initiative has demonstrated that New York State is addressing global health concerns while delivering on its goal of economic development and growing the life science ecosystem.”